RXST · Insider Trading
RxSight, Inc. Common Stock
Every open-market purchase and sale reported by RXST officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | Eric Weinberg | See remarks | M | +35,168 | +$152.63K |
| 2026-09-09 | Ronald M MD Kurtz | Chief Medical Officer | MIXED | −216,372 deriv. | — |
| 2026-09-09 | Mark Wilterding | Chief Financial Officer | MIXED | — | — |
| 2026-09-09 | Ilya Goldshleger | Chief Operating Officer | MIXED | −121,535 deriv. | — |
| 2026-09-09 | Eric Weinberg | See remarks | MIXED | −115,562 deriv. | — |
| 2026-09-02 | Mark Wilterding | Chief Financial Officer | MIXED | +12,676 | −$54.04K |
| 2026-09-02 | Ronald M MD Kurtz | Chief Medical Officer | MIXED | +8,325 | −$35.50K |
| 2026-09-02 | Ilya Goldshleger | Chief Operating Officer | MIXED | +3,329 | −$14.21K |
| 2026-09-02 | Eric Weinberg | See remarks | MIXED | +3,329 | −$14.21K |
| 2026-07-24 | Aziz Mottiwala | President and CEO | A | +2,883,424 deriv. | — |
| 2026-06-18 | Robert Keith Warner | Director | A | +37,037 | — |
| 2026-06-18 | Tamara Fountain | Director | A | +37,037 | — |
| 2026-06-18 | William J Phd Link | Director | A | +37,037 | — |
| 2026-06-18 | Robert J Palmisano | Director | A | +37,037 | — |
| 2026-06-18 | Bakker Juliet Tammenoms | Director | A | +37,037 | — |
| 2026-06-18 | Julie Andrews | Director | A | +37,037 | — |
| 2026-06-18 | Raymond W Cohen | Director | A | +30,864 | — |
| 2026-06-18 | Shweta Maniar | Director | A | +37,037 | — |
| 2026-06-18 | Jesse Anderson Corley | Director | A | +37,037 | — |
| 2026-04-20 | Ilya Goldshleger | Chief Operating Officer | M | +12,489 | +$51.58K |
| 2026-03-03 | Ilya Goldshleger | Chief Operating Officer | A | +32,218 deriv. | — |
| 2026-03-03 | Eric Weinberg | See remarks | A | +32,218 deriv. | — |
| 2026-03-03 | Ronald M MD Kurtz | President & CEO | A | +80,545 deriv. | — |
| 2026-03-03 | Scott Gaines | Chief Customer Officer | MIXED | +3,681 | −$19.63K |
| 2026-03-03 | Mark Wilterding | Chief Financial Officer | MIXED | +12,373 | −$61.40K |
| 2026-01-30 | Mark Wilterding | Chief Financial Officer | A | +422,298 deriv. | — |
| 2025-09-26 | Ilya Goldshleger | See remarks | M | +23,445 | +$100.00K |
| 2025-08-04 | Raymond W Cohen | Director | A | +35,668 | — |
| 2025-06-04 | Shweta Maniar | Director | A | +10,752 | — |
| 2025-06-04 | Tamara Fountain | Director | A | +10,752 | — |
| 2025-06-04 | Julie Andrews | Director | A | +10,752 | — |
| 2025-06-04 | Bakker Juliet Tammenoms | Director | A | +10,752 | — |
| 2025-06-04 | Robert Keith Warner | Director | A | +10,752 | — |
| 2025-06-04 | Jesse Anderson Corley | Director | A | +10,752 | — |
| 2025-06-04 | Robert J Palmisano | Director | A | +10,752 | — |
| 2025-06-04 | William J Phd Link | Director | A | +10,752 | — |
| 2025-06-03 | Eric Weinberg | See remarks | M | +188,002 | +$738.85K |
| 2025-04-15 | Shelley B Thunen | See remarks | M | +7,792 | +$33.81K |
| 2025-03-13 | Tamara Fountain | Director | Sell | −7,000 | −$180.00K |
| 2025-02-27 | Eric Weinberg | See remarks | A | +125,000 deriv. | — |
| 2025-02-27 | Ronald M MD Kurtz | President & CEO | A | +215,000 deriv. | — |
| 2025-02-27 | Shelley B Thunen | See remarks | A | +125,000 deriv. | — |
| 2025-02-27 | Ilya Goldshleger | See remarks | A | +125,000 deriv. | — |
| 2025-01-27 | Shweta Maniar | Director | Sell | −3,519 | −$108.62K |
| 2025-01-17 | Jesse Anderson Corley | Director | Buy | +3,210 | +$100.00K |
| 2024-12-03 | Ilya Goldshleger | See remarks | MIXED | — | −$96.25K |
| 2024-11-26 | Shweta Maniar | Director | Sell | −3,782 | −$173.52K |
| 2024-11-26 | Ilya Goldshleger | See remarks | MIXED | — | −$188.23K |
| 2024-11-18 | Ilya Goldshleger | See remarks | MIXED | — | −$243.49K |
| 2024-11-14 | Ilya Goldshleger | See remarks | MIXED | — | −$41.30K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Ronald M MD Kurtz | Chief Medical Officer | 836,385 | $4.06M |
| Eric Weinberg | See remarks | 535,494 | $2.60M |
| William J Phd Link | Director | 96,140 | $467.24K |
| Jesse Anderson Corley | Director | 93,310 | $453.49K |
| Bakker Juliet Tammenoms | Director | 86,731 | $421.51K |
| Robert Keith Warner | Director | 85,296 | $414.54K |
| Ilya Goldshleger | Chief Operating Officer | 82,881 | $402.80K |
| Robert J Palmisano | Director | 78,076 | $379.45K |
| Julie Andrews | Director | 78,076 | $379.45K |
| Tamara Fountain | Director | 72,582 | $352.75K |
| Raymond W Cohen | Director | 66,532 | $323.35K |
| Shweta Maniar | Director | 55,172 | $268.14K |
| Shelley B Thunen | See remarks | 38,354 | $186.40K |
| Mark Wilterding | Chief Financial Officer | 32,814 | $159.48K |
| Scott Gaines | Chief Customer Officer | 14,848 | $72.16K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RXST quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.